Department of Pharmaceuticals recommends export of 2000 MT in respect of Paracetamol API

The National Pharmaceutical Pricing Authority (NPPA) has allowed six major manufacturers of paracetamol active pharmaceutical ingredients (APIs) to export 2000 metric tonnes of paracetamol API. The recommendations has been issued by the Ministry of Home and Affairs.

The manufacturers mentioned below are allowed to export Paracetamol API, due to surplus availability:

Farmson Pharmaceutical -456 MT
Meghmani LLP- 209 MT
Sri Krishna Pharmaceuticals – 474 MT
Granules India- 655 MT
Bharat Chemicals- 91 MT
Para Products- 115 MT

“This is a progressive step initiated by the government by allowing the large manufacturers of paracetamol to begin the export. Since the Ministry of External Affairs is monitoring the activities of paracetamol and hydroxychloroquine (HCQ) in a licensed category and their demand position would be continuously monitored by them based on the stock position, companies would be allowed to fulfil the export commitments. The permission to export paracetamol raw materials for six large manufacturers is an encouraging step by the government. It also indicates that there will be smooth functioning of pharma exports. We look forward to permissions for other merchant exporters as well in the coming days.” Mahesh Doshi, President, Indian Drugs Manufacturers Association (IDMA) said.

B R Sikri, Chairman, Federation of Pharma Entrepreneurs (FOPE) said, “FOPE appreciates the move of the government of increasing the quantity of export of paracetamol APIs. The earlier quantity was almost 50 per cent of the current allocation, which is now 2000 metric tonnes. It shows how seriously the government is monitoring production, stock, materials in the pipeline as well as the demand-supply scenario. This is what is needed. This efficient way of working by the government will bring more such positive decisions in days to come so that neither our own people suffer for want of API or finished dosages nor the world markets which look towards India.”

  • Related Posts

    • Pharma
    • April 16, 2024
    • 32 views
    Significant Decline In Pharma Deals In Q1

    NEW DELHI: The pharma and healthcare sector witnessed a significant 15% decline in volume in the first quarter this year, with 47 deals amounting to $ 409 million, as against the…

    • Pharma
    • April 16, 2024
    • 23 views
    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    Ahmedabad: Imagine a bacterial infection with no known cure — a relentless adversary that defies conventional treatments and leads to prolonged illness and hospitalization. This was the condition of nine people…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Significant Decline In Pharma Deals In Q1

    Significant Decline In Pharma Deals In Q1

    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    CDSCO Releases Draft Guidance To Align New Drugs And Clinical Trials Rules And SUGAM For Stakeholder’s Comments

    CDSCO Releases Draft Guidance To Align New Drugs And Clinical Trials Rules And SUGAM For Stakeholder’s Comments

    Glenmark recalls 6,528 bottles of BP drug in US

    Glenmark recalls 6,528 bottles of BP drug in US

    Pharma Exports To US Surges 15% In 11 Months Of FY24

    Pharma Exports To US Surges 15% In 11 Months Of FY24

    CAHO Naa Patients Se Pyaar Hai

    CAHO Naa Patients Se Pyaar Hai